

India

Support for Vaccine: Pneumococcal conjugate vaccine (PCV) This Decision Letter sets out the Programme Terms of a Programme

1.	Country: India							
2.	Vaccine grant r	number: ۱۱	ND-PCV-R					
3.	Date of Decisio	n Letter:	10 March 20	21				
4.	Date of the Partnership Framework Agreement: 16 June 2015							
5.	Programme title: New Vaccine Support (NVS), Pneumococcal conjugate vaccine (PCV), Routine							
6.	Vaccine type: Pneumococcal conjugate vaccine (PCV)							
7.	Requested product presentation and formulation of vaccine: PCV10, 5 doses/vial, liquid							
8.	Programme dura	ation: ¹ 20	17-2021					
9.	Programme Budget (indicative): ² (subject to the terms of the Partnership Framework Agreement, if applicable)							
		2017-2020	2021	2022	2023	2024	2025	Total ²
	Programme Budget(US\$)	179,691,526	19,999,575	-	-	-	-	199,691,101
10.	Vaccine introdu	ction grant:						
10.	Vaccine introdu	ction grant.		Not app	licable			
11.	Product switch	grant:		Not app	licable			

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

¹This is the entire duration of the programme.

²This is the total amount endorsed by Gavi for the entire duration of the programme.

³This is the amount that Gavi has approved.



12. Indicative annual amounts:3

(subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2017-2020	2021	2022
Number of vaccine doses	-	9,385,000	-
Number of AD syringes	-	-	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	-	-
Annual Amounts (US\$)	179,691,526	19,999,575	-

13. Pro	curement	agency:	UNICEF	Supply	Division
---------	----------	---------	--------	--------	----------

14.	Self-	procurement:
-----	-------	--------------

Not applicable

15. Co-financing obligations:

Not applicable

Operational support for campaigns: 16.

Not applicable

Additional Reporting Requirements: 17.

Reports and other information :	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year:	
 vaccine stock levels including buffer stock, by end of March; 	31 March
 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May
 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

Financial clarifications:



Not applicable

19. Other conditions:

Not applicable

Signed by, On behalf of Gavi,

Pascal Bijleveld Director Country Support 10 March 2021